Combination Testing of Cediranib (AZD2171) against Childhood Cancer Models by the Pediatric Preclinical Testing Program

BACKGROUND: Cediranib (AZD2171) is a potent small molecule inhibitor of vascular endothelial growth factor VEGF receptors. Cediranib has demonstrated single agent activity in several adult cancers and is being studied in combination with standard cytotoxic agents in multiple disease settings. PROCED...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Morton, Christopher L., Maris, John M., Keir, Stephen T., Gorlick, Richard, Kolb, E. Anders, Billups, Catherine A., Wu, Jianrong, Smith, Malcolm A., Houghton, Peter J.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2011
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3253323/
https://ncbi.nlm.nih.gov/pubmed/21538824
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.23159
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky